Eli Lilly And Company Announces New Exploratory Phase 3b Data On Taltz And Zepbound In Adults With Psoriasis And Obesity

Roche, Novartis, Pfizer, and Eli Lilly received FDA approvals for their drugs. Lupin and Lipocine also gained regulatory nods. Caribou Biosciences plans to cut workforce and discontinue programs. Several biopharma companies announced deals and partnerships. Stock prices for mentioned companies varied.

Eli Lilly's phase 3b TOGETHER-PsO trial showed its combination treatment of Taltz and Zepbound improved outcomes for patients with moderate-to-severe plaque psoriasis who are overweight or obese. The company's GF Value™ suggests it is modestly undervalued with a 25.4% margin of safety, and its GF Score™ is 98 out of 100, indicating strong financial health. Insiders have been net sellers, while 25 premium gurus hold LLY, with 12 adding and 10 trimming positions.

Eli Lilly (LLY) presented data from its Phase 3b TOGETHER-PsO trial, showing that combining Taltz (psoriasis treatment) with Zepbound (obesity therapy) led to broader biomarker changes than Taltz alone. The study suggests interconnected immune and metabolic pathways in patients with both psoriasis and obesity. LLY stock closed at $1,169.60, down 1.61%.

Eli Lilly presented new data from a Phase 3b trial showing that the combination of Taltz and Zepbound may benefit obese or overweight psoriasis patients. The company claims the results support a more integrated treatment approach for these patients, addressing both immunological and metabolic aspects. According to Lilly, psoriasis and obesity often coexist in 61% of U.S. patients.

Eli Lilly's experimental drug, retatrutide, helped Type 2 diabetes patients lose 20.8% of their body weight in an 80-week trial. The highest dose group saw an average weight reduction of 49.6 pounds. The drug also improved blood sugar control, with 40% of participants on the two highest doses achieving normal blood sugar levels. The results were presented at the European Association for the Study of Diabetes meeting and published in The Lancet.

Eli Lilly reported Phase 3b data showing combined Taltz and Zepbound treatment led to broader changes in psoriasis-related, immune, and metabolic biomarkers compared to Taltz alone. The study involved adults with psoriasis and obesity or overweight. LLY closed at $1,169.60, down 1.61%, and is down 0.51% in pre-market trading.